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A composite construct comprising of a bone mesenchymal stem cell (BMSC) sheet, plasmid DNA, encoding human bone mor-
phogenic protein-2 (hBMP-2), and poly(lactide-co-glycolide)/hydroxyapatite (PLGA/HA) sponge was designed and employed in 
the restoration of rat calvarial defects. To improve gene transfection efficiency, a cationic chitosan derivative, N,N,N,-trimethyl 
chitosan chloride (TMC), was employed as the vector. The TMC/DNA complexes had a transfection efficiency of 13% in rat 
BMSCs, resulting in heterogeneous hBMP-2 expression in a 10-d culture period in vitro. In vivo culture of the composite con-
structs was performed by implantation into rat full-thickness calvarial defects, using constructs lacking pDNA-hBMP-2 or BMSC 
sheets as controls. Significantly higher heterogeneous expression of hBMP-2 was detected in vivo at 2 weeks for the cell 
sheet/DNA complex/scaffold constructs, compared with the constructs lacking pDNA-hBMP-2 or BMSC sheets. New bone for-
mation was evident as early as 4 weeks in the experimental constructs. At 8 weeks, partial bridging of calvarial defects was ob-
served in the experimental constructs, which was significantly better than the constructs lacking pDNA-hBMP-2 or BMSC sheets. 
Therefore, the combination of the PLGA/HA scaffold with BMSC sheets and gene therapy vectors is effective at enhancing bone 
formation.  
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Bone regeneration is one of the hot topics of research in the 
field of regenerative medicine. Many strategies have been 
investigated in bone tissue engineering, including cell-based 
strategies, scaffold development and growth factor delivery. 
The combination of regenerative medicine and gene therapy 
offers new opportunities to target multiple factors at once, 
which may help increase the potential of these techniques 
for promoting bone repair. 
Numerous growth factors currently used in bone tissue 
engineering, including bone morphogenic protein-2 (BMP- 
2), which is well-known for its powerful ability to commit 
mesenchymal stem cells (MSCs) towards an osteogenic 
lineage and induce new bone formation [1]. However, a 
major limitation of growth factors is that they can be expen-
sive and generally have a short-half life. Gene therapy has 
been investigated as an alternative method for BMP deliv-
ery and there has been some evidence that proteins synthe-
sized endogenously as a result of gene transfection have 
greater biologic activities than their recombinant counter-
parts [2]. The general protocol for gene therapy in tissue 
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repair is to transplant cells transfected by gene/vector com-
plexes in vitro [3]. However, prolonged expression of the 
proteins from in vitro transfected cells is dependent on the 
survival of the transplanted cells during implantation and 
within the defect. An alternative protocol is to directly load 
the gene or gene/vector complexes into the scaffold, result-
ing in the seeded cells and/or endogenous cells being trans-
fected in situ [4,5]. To enhance the body’s innate capacity to 
repair bone defects after injury, composite scaffolds of 
polymer and ceramic particles are preferred because of their 
favorable mechanical properties and bioactivity [6,7]. Pre-
viously, we have developed a poly(lactide-co-glycolide) 
(PLGA) scaffold with hydroxyapatite nanoparticles embed-
ded in the pore walls (PLGA/HA), which enhanced osteo-
blastic differentiation of bone marrow stem cells (BMSCs) 
in vitro [8].  
Compared with the traditional method of directly seeding 
cells in scaffolds, the cell sheet technique makes it possible 
to deliver a much larger number of cells for efficient tissue 
regeneration [9]. The cell sheet can be easily detached from 
the culture substrate using a cell-scraper, which enables the 
extracellular matrix and cell-cell interactions to remain in-
tact as no enzymatic treatments are used. Recent studies 
have shown that the cell sheet technique is effective for the 
treatment of myocardial infarction [10], tendon defects [9] 
and periodontitis [11]. The cell sheet technique contributes 
to bone formation in cases of osseointegration [12], nonun-
ion [13], various bone defects [14,15] and spinal interbody 
fusion [16]. 
To the best of our knowledge, there is no report on the 
fabrication of a composite construct integrated with a 
PLGA/HA scaffold, BMSC sheet and gene therapy for bone 
regeneration. The aim of this study is to evaluate the feasi-
bility of this method for bone formation in rat calvarial de-
fect models.  
1  Materials and methods 
1.1  Materials 
Poly(lactide-co-glycolide) (PLGA, 75/25 lactide/glycolide 
ratio, Mn=78.5 kD, Mw=132.4 kD) was purchased from 
China Textile Academy. Paraffin (melting point, 53–56°C), 
1,4-dioxane and hexane were obtained from Shanghai 
Chemical Industries Co., Ltd. Dulbecco’s modified Eagle’s 
medium (DMEM) and fetal bovine serum (FBS) were ob-
tained from GIBCO (Life Technologies, Grand Island, New 
York, USA). Quant-iT™ PicoGreen dsDNA reagent (an in-
tercalating fluorescent dye) was purchased from Invitrogen 
(Life Technologies). Hochest 33258 and methyl tetrazolium 
(MTT) were obtained from Sigma (Sigma-Aldrich, St. Lou-
is, MO, USA). Millipore water was used throughout the 
study. All other reagents were of analytical grade and used 
as received. 
1.2  Cell culture and cell sheet preparation 
Bone marrow stem cells (BMSCs) were isolated from the 
bone marrow of young adult male Sprague-Dawley rats as 
previously described [17]. The procedures were performed 
in accordance with the “Guidelines for Animal Experimen-
tation” by the Institutional Animal Care and Use Committee, 
Zhejiang University. Briefly, bone marrow cells were ob-
tained from the femoral shafts of rats by flushing out with 
10 mL of culture medium (low glucose DMEM supple-
mented with 10% FBS, 100 μg/mL penicillin and 100 U/mL 
streptomycin). The released cells were collected in two 
flasks (75-cm2 culture flask, Corning Inc., USA) containing 
15 mL culture medium and incubated in a humidified atmos-
phere of 95% air with 5% CO2 at 37°C. After reaching about 
80% confluency, cells were detached and serially subcultured. 
BMSCs at passage 2 (P2) were used in this study.  
To prepare the cell sheet, BMSCs of P2 were harvested, 
reseeded in flasks (25-cm2 culture flask, Corning Inc.), and 
cultured in low-glucose DMEM with 10% FBS for about 
two weeks without passaging. The culture medium was 
changed every 2 d. BMSC sheets formed spontaneously and 
could be detached intact from the substrate using a cell- 
scraper (Figure 1(a)). About 4.6×106 cells were contained 
within a single cell sheet, as determined by DNA quantifi-
cation using a fluorometer (LS55, Perkin-Elmer, Waltham, 
MA, USA) with the fluorescent dye Hoechst 33258 [18]. 
1.3  Preparation of TMC/DNA complexes 
N,N,N-trimethyl chitosan chloride (TMC) was synthesized 
according to the previously reported method [19]. The 
chemical structure of the product was characterized by 1H 
NMR spectroscopy (300 MHz, Varian, Agilent Technolo-
gies, Santa Clara, CA, USA). The chemical shifts with peak 
positions at δ 3.2 and 2.0 were assigned to –N(CH3)3+ and 
–COCH3, respectively, according to which the degree of 
quaternization was determined to be 38%. 
TMC and DNA were dissolved in Millipore water to ob-
tain 1 mg/mL solutions, which were filtered through syringe 
filters (Durapore, Millipore, Billerica, MA, USA) with a 
pore size of 0.22 m for sterilization. The TMC solution 
was added to the DNA solution and vortexed vigorously for 
30 s, and further incubated for 30 min at 37°C before use or 
characterization. The N/P ratio (molar ratio of amine groups 
to phosphate groups) used in this study was fixed at 10, as 
TMC/DNA complexes of this ratio have the highest trans-
fection efficiency in vitro [19]. The morphology and the 
mean diameter of the TMC/DNA complexes were charac-
terized by scanning electron microscopy (SEM, JEOL JEM- 
200CX, Tokyo, Japan). 
1.4  In vitro cytotoxicity and gene transfection evaluation 
The cytotoxicity of different concentrations of TMC/DNA  
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Figure 1  Macroscopic images of (a) BMSC sheet, (b) PLGA/HA scaffold, (c) PLGA/HA/pDNA complexes/cell sheet construct, and (d) rat calvarial de-
fects with a diameter of 5 mm. SEM images of (e) PLGA/HA scaffold, and (f) PLGA/HA scaffold wrapped in a BMSC sheet. 
complexes was evaluated via MTT assay [19]. Briefly, 
BMSCs were seeded in a 96-well plate at a concentration of 
5×103 cells per well and cultured overnight. The culture 
medium was then removed and 100 μL DMEM/10% FBS 
containing 10 μg naked DNA or TMC/DNA particles with 
normalized DNA concentrations of 0.2, 2 or 10 μg per 104 
BMSCs were added to each well. BMSCs cultured in nor-
mal DMEM/10% FBS medium without DNA were used as 
a control. The culture medium was exchanged with the cor-
responding medium for each of the groups every 2 d 
throughout the culture period. Each value was averaged 
from three parallel experiments. 
The transfection efficiency was determined by 2D culture 
using pDNA-eGFP. Briefly, 5×104 BMSCs were seeded 
into each well of a 12-well culture plate and cultured over-
night. After the culture medium was removed, the TMC/ 
pDNA-eGFP complexes (2 μg DNA per 104 BMSCs) were 
added with DMEM. Eight hours later, the culture medium 
was exchanged with DMEM containing FBS. The cells 
were detached from the plate after 3 d and characterized by 
flow cytometry (FACS, FACSCalibur, BD Bioscience, 
Franklin Lakes, NJ, USA).  
The extent of hBMP-2 expression in vitro was deter-
mined using pDNA-hBMP-2, rather than pDNA-eGFP, and 
quantified using an ELISA kit (RapidBio, West Hills, CA, 
USA), following the manufacturer’s instructions. The cell 
density was determined by DNA quantification using a flu-
orometer (LS55, Perkin-Elmer) with the fluorescent dye 
Hoechst 33258 [18]. After correlating the DNA quantity 
with the cell number by a standard curve, the average 
hBMP-2 expression level per 105 cells was calculated. All 
data were averaged from three parallel measurements. 
1.5  Preparation of DNA-loaded PLGA/HA Scaffolds 
PLGA/HA Scaffolds were fabricated by a porogen-leaching 
method as previously described [8]. Briefly, the HA nano-
particle-coated paraffin spheres were prepared via Pickering 
emulsion. The sieved HA-coated paraffin spheres (450–600 
µm) were added into a Teflon mold, which was incubated in 
an oven at 45°C for 30 min to bind the spheres. After cool-
ing to room temperature, around 1 mL 12% PLGA/1,4-  
dioxane solution was cast dropwise onto the HA-coated 
paraffin sphere assembly. The system was subsequently 
frozen at –25°C for 2 h and then freeze-dried to remove the 
1,4-dioxane. The PLGA/HA porous scaffolds were finally 
obtained by leaching the paraffin assembly in 400 mL hex-
ane at 37°C for 2 d, changing the hexane every 4 h. To ob-
serve the inner microstructure under SEM, the porous scaf-
folds were fractured in liquid nitrogen. The porosity of the 
scaffolds was determined by ethanol inhalation [20]. 
PLGA/HA scaffolds, with an average diameter of 5 mm 
and a height of 1 mm (Figure 1(b)), were sterilized with  
75 vol% ethanol for 4 h and incubated in phosphate-buffered 
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saline (PBS) for 1 d to exchange the ethanol solution. 
TMC/DNA complex solution (0.2 mg/mL DNA) was used 
to fill the pores of the scaffolds, which were then kept at 
4°C overnight and freeze-dried to facilitate the complete 
incorporation of the TMC/DNA complexes.  
Each PLGA/HA scaffold containing TMC/DNA com-
plexes was immersed in 0.5 mL of 25 mg/mL papain/PBS 
solution containing 4 mg/mL EDTA and digested overnight 
at 60°C. The total loaded amount of DNA on the scaffolds 
was assessed by fluorometry (LS55, Perkin-Elmer) using 
PicoGreen at excitation and emission wavelengths of 480 
and 520 nm, respectively. An in vitro release assay was 
conducted to determine the release kinetics of DNA from 
the PLGA/HA scaffolds. Each of the PLGA/HA scaffolds 
containing the TMC/DNA complexes was immersed in    
1 mL of sterile PBS and gently stirred at 37°C. At desired 
time intervals, 0.2 mL of the supernatant was collected for 
analysis and replaced with an equal volume of fresh PBS. 
The 0.2 mL supernatant was added into 0.3 mL of 25 
mg/mL papain/PBS solution containing 4 mg/mL EDTA 
and digested overnight at 60°C. The quantity of the released 
DNA was analyzed by fluorometry with PicoGreen. All 
data were averaged from three parallel measurements and 
expressed as mean ± standard deviation (SD). 
1.6  Surgical procedures 
To prepare the implants, the BMSC sheet was wrapped 
around the scaffold with or without the incorporation of 
TMC/DNA complexes. The implants were divided into 
three groups as follows: 
Group A, PLGA/HA/(TMC/pDNA-hBMP-2 complexes)/ 
cell sheet; n = 18; 
Group B, PLGA/HA/cell sheet; n = 16; 
Group C, PLGA/HA/(TMC/pDNA-hBMP-2 complexes); 
n = 18. 
Three samples from each group were used to study the in 
vivo expression of hBMP-2 in rat calvarial defects after 2 
weeks of implantation by qRT-PCR. Another 3 samples 
from each group were used for micro-computed tomogra-
phy after 8 weeks of implantation and were subsequently 
used for hematoxylin and eosin (H&E) staining. A total of 5 
samples from each group were used for H&E staining after 
implantation for 4 and 8 weeks, respectively. Three samples 
in each group were used for analysis of gene expression in 
repaired tissues after 8 weeks of implantation. 
Twenty-five 12–13-week-old male Sprague-Dawley rats 
(250–300 g) were housed in a light- and temperature-  
controlled environment, with free access to food and water. 
The rats were anaesthetized by injection of ketamine hy-
drochloride (3.5 mg/kg of body weight; China National 
Medicines Corporation Ltd, Beijing, China) into the perito-
neal cavity. For the calvarial defect model, the dorsal part of 
the cranium was shaved and a linear incision of approxi-
mately 20 mm was opened over the scalp of each animal. 
The periosteum was removed and two full-thickness calvar-
ial defects were prepared (5 mm in diameter) in the parietal 
bone using a slow speed dental drill (Figure 1(d)). Constant 
saline irrigation was performed and the dura mater was kept 
intact during the procedure. After placement of the con-
structs into the defects, the skin was sutured.  
1.7  Micro-computed tomography (µCT) and histology 
The rats were euthanized after implantation for 4 or 8 weeks. 
Block samples, including the surgical sites, were harvested 
and fixed in 4% paraformaldehyde at 37°C for 48 h. Three 
samples at 8 weeks from each group were scanned using a 
micro-CT system (Explore Locus; GE Healthcare, Chalfont 
St. Giles, Buckinghamshire, UK) in a high-resolution scan-
ning mode (voxel size and slice thickness of 45 µm). 
Three-dimensional images were reconstructed, and the 
volume of the regenerated bone within the defects was cal-
culated using the auxiliary software, MicroVIEW (GE 
Healthcare).  
For histological examination, samples were decalcified in 
10% EDTA for 3 weeks at room temperature, dehydrated 
using an ascending alcohol gradient and embedded in paraf-
fin. Longitudinal sections were stained with H&E and visu-
alized using an optical microscope (DXM200F Digital 
Camera; Nikon, Tokyo, Japan). Five defects per group were 
analyzed at each time point. 
1.8  Quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR)  
In vivo expression of hBMP-2 was determined by qRT-PCR 
in rat calvarial defects two weeks post-implantation and in 
repaired tissues at 8 weeks. Three samples were used for 
each assay (n=3). Total RNA was extracted using the RNe-
asy Mini Kit (Qiagen, Montgomery, AL, USA) and ~1 μg 
of total RNA was used for reverse-transcription into cDNA 
with the Omniscript RT Kit (Qiagen). QRT-PCR of 
hBMP-2, type I collagen (COL I) and osteocalcin (OCN) 
was performed in an ABI 7300 real-time PCR system (Ap-
plied Biosystems, Life Technologies) with SYBR Green 
PCR master mix (Applied Biosystems), under the following 
conditions: 15 s at 90°C, 60 s at 60°C, with the fluorescence 
intensity being recorded for 40 cycles. CT (threshold cycle) 
values were calculated using the iQ5 optical system soft-
ware (Version 2, Bio-Rad, Berkeley, CA, USA). The 
mathematical model previously described in detail was used 
to determine the expression ratio of genes [21]. Primer  
sequences used in quantitative real-time PCR were GAPDH 
sense, 5′-GGTGGACCTCATGGCCTACAT-3′; GAPDH  
antisense, 5′-GCCTCTCTCTTGCTCTCAGTATCCT-3′; 
hBMP-2 sense, 5′-CCAAGATGAACACAGCTGGTCA- 
CAGA-3′; hBMP-2 antisense, 5′-CCCACGTCACTGAAG- 
TCCACG-3′; Rat collagen I sense, 5′-ACCTCCGGCTCCT- 
GCTCCTCTTAG-3′; Rat collagen I antisense, 5′-GACA- 
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GCACTCGCCCTCCCGTTTTT-3′; Rat Osteocalcin sense, 
5′-CTCACTCTGCTGGCCCTGAC-3′; Rat Osteocalcin anti- 
sense, 5′-CACCTTACTGCCCTCCTGCTTG-3′. 
1.9  Statistics 
Data are expressed as mean ± SD. Statistical analysis was 
performed by two-tailed Student’s t-tests between two 
groups. All statistical computations were performed using 
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 
was considered statistically significant. 
2  Results 
2.1  Properties of the composite construct 
The BMSC sheet could be detached intact with a cell- 
scraper as depicted in Figure 1(a), and wrapped tightly 
around the PLGA/HA scaffold loaded with DNA/TMC 
complexes (Figure 1(c)). The PLGA/HA sponges (Figure 
1(b),(e)) used in this work were prepared by a porogen- 
leaching method using HA-coated paraffin spheres of 
450–600 μm diameter as the porogen. As the average pore 
size was larger than 450 μm, the porosity measured by eth-
anol inhalation was ~90%. Their size matched exactly the 
size of the calvarial defects (Figure 1(d)). By comparison 
with the pristine sponge (Figure 1(e)), the cell sheet wrap-
ping resulted in dense and uniform cells on the construct 
surface (Figure 1(f)). 
As shown in Figure 2(a), the positively-charged TMC 
could effectively condense the negatively-charged DNA and 
yield small particles with an average diameter of ~100 nm, 
as detected by SEM in a dry state. All the complexes were 
well dispersed with a typical spherical morphology.  
The cell viability of rat BMSCs exposed to different 
concentrations of TMC/DNA complexes or naked DNA 
was evaluated by MTT assay (Figure 2(b)). For direct com-
parison, the OD values measured from the TMC/DNA or 
naked DNA samples were normalized to those of the con-
trol samples (cells cultured in normal DMEM/10% FBS 
medium). When the concentration of TMC/DNA complexes 
was lower (e.g. 0.2 μg DNA per 104 BMSCs), the cell via-
bility increased during culture and was significantly larger 
than that of the control sample at day 7 (P < 0.05). Cyto-
toxicity was apparent at higher TMC/DNA concentrations, 
with cell viability decreasing to around 1/4 of the control 
sample at day 7 when the DNA concentration was increased 
to 10 μg DNA per 104 BMSCs. By contrast, cells cultured in 
medium containing naked DNA (10 μg DNA per 104 
BMSCs) showed comparable viability to that of the control 
at day 7, indicating that the naked DNA is not cytotoxic. 
Considering the balance between the efficacy and cytotoxi-
city, an intermediate concentration (2 μg DNA per 104 
BMSCs) of TMC/DNA complexes was used for the later 
studies. 
TMC/pDNA-eGFP complexes were co-cultured with 
BMSCs in a 2D culture system. FACS was used to calculate 
the percentage of cells which expressed GFP and the mean 
fluorescence intensity. Figure 3(a) shows fluorescence in-
tensity increasing from 6 to 17 after transfection. Consider-
ing that cells with relative fluorescence intensity higher than 
10 are regarded as GFP-transfected cells, the gene transfec-
tion efficiency detected by FCM was ~13%. Following this, 
BMSCs were transfected with pDNA-hBMP-2/TMC com-
plexes to detect growth factor production. As shown in Fig-
ure 3(b), BMSCs could effectively express hBMP-2 after 
transfection, with the concentration in the supernatant in-
creasing only slightly during the experimental period until 
the longest determined time-point (10 d). 
Each PLGA/HA scaffold adsorbed 2 μg of DNA. Figure 
4 shows that the DNA was released rapidly during the first 
4 h, with ~74% being released in this period. However, the 
residual DNA was released at a much slower rate until 72 h, 




Figure 2  (a) SEM image of TMC/DNA complexes. (b) BMSC viability as a function of culture time. TMC/DNA complexes with a fixed N/P ratio of 10 or 
naked DNA were added to the culture medium with different concentrations of DNA (0.2, 2 and 10 g per 104 BMSCs). The viability was normalized to that 
of control samples without DNA. 
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Figure 3  (a) Average fluorescence intensity of BMSCs before and after transfection with the TMC/plasmid DNA-eGFP complexes in vitro (2 μg plasmid 
DNA-eGFP per 104 BMSCs). Data were obtained by flow cytometry. *, P < 0.05. (b) In vitro hBMP-2 expression in the supernatant after transfection with 
TMC/pDNA-hBMP-2 complexes.  
 
Figure 4  Cumulative released amount of DNA (TMC/DNA complexes, 
N/P=10) from PLGA/HA scaffold as a function of incubation time. 
 
Figure 5  In vivo expression of hBMP-2 in rat calvarial defects for 2 
weeks evaluated by qRT-PCR. Group A, PLGA/HA/(TMC/pDNA- 
hBMP-2 complexes)/cell sheet; Group C, PLGA/HA/(TMC/pDNA-hBMP- 
2 complexes). The gene expression level was normalized to that of the 
respective GAPDH expression. *, P < 0.05. 
 
 
demonstrate that the DNA complexes could be easily re-
leased from the scaffold, which is as expected as only weak 
physical interactions exist. However, the in vivo release 
pattern, in particular after the stem cell entrapment, should 
be different because of the physical confinement of host 
tissues.  
2.2  In vivo hBMP-2 expression  
As the pDNA-hBMP-2 used in this study originated from 
human, it can effectively avoid the interference of host pro-
teins produced by the rat. QRT-PCR analysis of hBMP-2 
expression in the defects demonstrated that much more 
hBMP-2 was expressed in Group A (PLGA/HA/(TMC/ 
pDNA-hBMP-2 complexes)/cell sheet) than Group C 
(PLGA/HA/(TMC/pDNA-hBMP-2 complexes)) after 2 
weeks of implantation (Figure 5). No hBMP-2 was detected 
by qRT-PCR in Group B (PLGA/HA/cell sheet).  
2.3  In vivo bone formation 
Bone formation was evident 4 weeks after implantation in 
Group A. The newly-formed bone (marked as B) was iden-
tified not only close to native bone but also in the centers of 
the defects (Figure 6(a),(d),(g)). Bone islands were also 
found in the centers of the defects in Group B (Figure 6(b), 
(e),(h)). No new bone was formed in Group C and only ob-
vious fibrous tissue (marked as F) could be observed in the 
defects (Figure 6(c),(f),(i)). Residual scaffolds (marked as S) 
were present in the defects in all three groups (Figure 
6(d)–(f)). 
Bone formation was enhanced after a longer healing time 
in Group A, which almost bridged the calvarial defect (Fig-
ure 7(a),(d),(g)). Many osteoblasts (marked with a black 
arrow) were trapped in the lacunae, and the new bone 
showed a more similar morphology to the host bone. No 
apparent increase in new bone formation was observed in 
Group B at 8 weeks (Figure 7(b),(e),(h)). Fibrous tissue  
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Figure 6  H&E staining photomicrographs of calvarial defect sites treated with (a, d, g) Group A, (b, e, h) Group B, and (c, f, i) Group C for 4 weeks. B, F, 
S and black arrows represent new bone, fibrous tissue, residual scaffold and osteoblasts, respectively. 
 
Figure 7  H&E staining photomicrographs of calvarial defect sites treated with (a, d, g) Group A, (b, e, h) Group B, and (c, f, i) Group C for 8 weeks. 
became denser in Group C, and a small amount of new bone 
was found at the edge of the bone defect (Figure 7(c),(f), 
(i)). Scaffolds had been degraded significantly but were still 
visible (Figure 7(d)–(f)). 
Micro-CT evaluations confirmed new bone formation at 
8 weeks post-implantation, especially in Group A (Figure 
8(a)–(c)). Bone-healing efficacy was improved in the se-
quence of Group C < Group B < Group A. Partial bridging 
was observed in Group A. Some bone islands were formed 
in the center of defects in Group B, but new bone was only 
regenerated in the periphery of defects in Group C. No 
complete bridging was observed in defects of all groups.  
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Figure 8  Representative micro-CT images of rat calvarial defects repaired by (a) Group A, (b) Group B, and (c) Group C for 8 weeks. The gray areas rep-
resent mineralized bone. (d) Quantitative bone volume analysis by micro-CT. *, P < 0.05. 
Volumetric analysis (Figure 8(d)) showed a significantly 
higher volume of new bone in Group A compared with 
Groups B and C (P < 0.05). The new bone volume in Group 
C was around half of that in the Group A. 
2.4  Analysis of gene expression  
Expression of bone-related genes was analyzed by qRT- 
PCR (Figure 9). The level of the 2 bone special genes of the 
Group A was significantly higher than that of the Groups B 
and C (P < 0.05). In Group A, the expression level of colla-
gen type I was 5- and 15-fold higher than Groups B and C, 
respectively. The expression level of osteocalcin in Group 
A was 2- and 5-fold higher than Groups B and C, respec-
tively. 
3  Discussion 
It is a primary focus of orthopedic research to develop reli- 
 
 
Figure 9  Gene expression profiles characterized by qRT-PCR for (a) collagen type I, and (b) osteocalcin in repaired tissues after implantation for 8 weeks. 
The gene expression level was normalized to that of the respective GAPDH expression. *, P < 0.05. 
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able approaches for the repair or regeneration of damaged 
bone [22,23]. Tissue engineering and regenerative medicine 
have shown great promise in promoting bone repair using 
MSC sheets alone or in combination with implants wrapped 
in MSC sheets [13,24]. Compared with the traditional 
method of directly seeding cells in scaffolds, the cell sheet 
technique makes it possible to deliver a much larger number 
of cells for efficient tissue regeneration [9]. As a potent reg-
ulator of cell function and differentiation, the extracellular 
matrix (ECM) can be well-preserved during cell sheet fab-
rication, thereby enhancing osteoblastic differentiation and 
improving bone formation [25]. Previous research demon-
strates that PLGA scaffolds with a HA coating (PLGA/ 
HA-S or PLGA/HA) have good mechanical properties and 
bioactivity [8]. However, PLGA/HA scaffolds are not suffi-
cient on their own at providing instructive cues for MSC 
osteoblastic differentiation and new bone formation. BMP-2 
is one of the most potent growth factors with a powerful 
ability to recruit MSCs and induce MSC osteoblastic dif-
ferentiation [26,27]. Using gene therapy, recombinant 
BMP-2 can be expressed in situ after transfection with a 
plasmid encoding BMP-2. Therefore, in this study we fab-
ricated a PLGA/HA scaffold, which was wrapped in a MSC 
sheet and complexed with gene therapy vectors, to repair rat 
calvarial defects with promising results.  
Firstly, based on our previous results, TMC with a 
quaternization degree of 38% was used as the vector to 
condense DNA and form nano-complexes [28]. These com-
plexes are beneficial to mask the strong negative charge of 
DNA and thereby facilitate uptake across the cell membrane 
[29]. Expression of hBMP-2 in vitro (Figure 3(b)) and in 
vivo (Figure 5) confirmed the success of the present gene 
delivery strategy.  
In the animal experiments, one experimental group, 
Group A (PLGA/HA/(TMC/pDNA-hBMP-2 complexes)/ 
cell sheet) and two control groups, Group B (PLGA/HA/cell 
sheet) without gene, and Group C (PLGA/HA/(TMC/ 
pDNA-hBMP-2 complexes)) without BMSC sheet, were 
used to determine the importance of both gene therapy and 
BMSC sheet incorporation on bone regeneration by the 
present protocol. Group A showed enhanced new bone for-
mation and up-regulation of bone-specific gene expression. 
This positive effect is reasonably attributed to the expres-
sion of hBMP-2 by the loaded TMC/pDNA-hBMP-2 com-
plexes and BMSC sheet. Indeed, the expression of hBMP-2 
was only detected in Groups A and C, with a significant 
higher level in Group A (Figure 5). Incorporation of the 
BMSC sheet significantly improved expression of hBMP-2; 
however, the BMSC sheet alone was unable to secrete de-
tectable hBMP-2 in Group B. The BMSC sheet was previ-
ously shown to secrete larger amounts of angiogenic and 
antiapoptotic factors by paracrine activity [10], which may 
be conducive to the migration of endogenous cells. Aside 
from the transfection of BMSCs, hBMP-2 expression could 
result from the transfection of endogenous cells, such as 
fibroblasts, which could then produce hBMP-2 [30]. The 
upregulation of osteocalcin, which is a terminal marker of 
osteoblastic differentiation, indicates the enhanced osteo-
blastic differentiation of BMSC sheets in Group A.  
We believe that the intrinsic mechanism behind the more 
efficient repair seen in the experimental group depends on 
both the incorporation of gene therapy and the stem 
cell-sheet technology. While the BMSC sheet is necessary 
to rebuild the bone ECM, the differentiation of BMSCs into 
osteoblasts is also required and is greatly enhanced by 
hBMP-2 gene therapy. Comparatively, the BMSC sheet 
plays a more important role, as bone regeneration was ob-
served in several small regions within the central portions of 
defects that were covered by the transplanted cell sheets 
alone [31]. Moreover, although cell labeling was not used in 
this research, by comparing the results between Groups A 
and C, it is safe to conclude that many osteoblasts in the 
neo-tissue of Group A are differentiated from the trans-
planted BMSC sheet. 
The results from the in vivo study indicate that the load-
ing of TMC/pDNA-hBMP-2 complexes into the PLGA/HA 
scaffolds is not sufficient to elicit a bone regeneration re-
sponse. This is in accordance with previous studies, in 
which scaffolds containing plasmid DNA did not result in 
enhanced bone formation [32,33]. The incorporation of 
TMC/pDNA-hBMP-2 complexes into PLGA/HA scaffolds 
also resulted in decreased bone formation compared with 
the delivery of recombinant BMP-2 protein with this system 
in our previous study (unpublished work). The reasons are 
unclear as several factors are involved during pDNA- 
hBMP-2 transfection as well as bone healing processes. One 
reason may be the low transfection efficiency seen, which 
may result in only low levels of BMP-2 being produced. 
This amount was in the range of pg in the in vitro study, 
which is far below the g value used in the previous study 
[34,35]. Thus, future studies should investigate more effi-
cient gene vectors capable of transfecting BMCs to a higher 
degree. 
4  Conclusion  
Herein, a bioactive construct of PLGA/HA/(TMC/pDNA- 
hBMP-2 complexes)/cell sheet was designed and manufac-
tured for bone regeneration; its biological performance was 
evaluated in a rat calvarial defect model. Gene complexes 
had a transfection efficiency of 13% in BMSCs in vitro, 
which expressed hBMP-2 both in vitro and in vivo. Implan-
tation of the constructs into full-thickness rat calvarial de-
fects with a diameter of 5 mm resulted in increased new 
bone formation. Osteogenic genes, such as collagen type I 
and osteocalcin, were also up-regulated, implying the effi-
cient osteogenic differentiation of BMSC sheets. Moreover, 
some small bone islands were also observed in the center of 
bone defects when a construct without the hBMP-2 gene 
444 Li D, et al.   Chin Sci Bull   February (2012) Vol.57 No.5 
was used. By contrast, when the BMSC sheets were used in 
the absence of the construct, minimal bone tissue was found 
in the calvarial defects. Therefore, combination of the 
PLGA/HA scaffold with BMSC sheets and gene therapy is 
more effective at restoring calvarial defects by the present 
method.  
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